Latest Financial Results News

Solvar Limited’s FY25 results highlight solid loan book growth in Australia, the strategic launch of Bennji commercial finance, and a significant 40% increase in dividends, underpinning confidence in future earnings.

Orcoda Limited reported a 33% drop in FY25 revenue to $17.16 million and a net loss of $2.5 million, driven by deferred projects in its Resource & Infrastructure division. Meanwhile, its Transport Technology division posted EBITDA growth, signaling a potential turnaround.

Anagenics has delivered a significant financial turnaround in FY25, driven by a strategic restructure, exiting loss-making operations, and securing new royalty agreements. Despite a revenue dip, the company improved profitability and cash flow, positioning itself for sustainable growth.

FINEOS Corporation delivered solid first-half results with revenue growth and improved profitability, while navigating currency challenges that temper full-year guidance.

WT Financial Group (ASX, WTL) reported a 20.5% rise in FY2025 net profit after tax to $4.6 million, driven by strong revenue growth and operational leverage. The company declared a fully-franked dividend of 0.7 cents per share, underpinned by its expanding B2B financial advice network and proprietary risk management framework.

Titomic Limited reported a 22.5% increase in revenue to $9.43 million for FY2025 but saw losses soar by over 67%, highlighting ongoing financial challenges despite growth.

Australian Unity Office Fund reports a $35.6 million loss for FY25 as it advances asset disposals ahead of planned delisting, with the final property sale facing settlement uncertainty.

Farm Pride Foods Ltd has reported a remarkable 384% increase in net profit for the financial year ending June 2025, despite revenues remaining virtually unchanged. The company’s financial health shows signs of strengthening, though no dividends were declared.

Clinuvel Pharmaceuticals has reported a robust financial year ending June 2025, marked by solid revenue growth and sustained profitability, while advancing its clinical pipeline and maintaining a strong balance sheet.

Horizon Oil Limited reported a 13% increase in production for FY25, driven by the Mereenie acquisition and infill drilling success, while completing a transformative acquisition of Thailand assets. Despite softer oil prices, the company declared a final unfranked dividend, underscoring robust cash flow and strategic growth.

Clinuvel Pharmaceuticals has reported its ninth consecutive year of revenue and profit growth, driven by strong sales of SCENESSE® and strategic investment in vitiligo clinical trials. The company also declared its eighth consecutive dividend, underscoring financial resilience.

RAS Technology Holdings Limited reported a robust 31% increase in revenue to A$21.3 million for FY25, alongside its first net profit after tax since listing, driven by strategic acquisitions and global expansion.